| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From Dartmouth Medical School (Dr. Mahler), Lebanon, NH; and Abgenix, Inc. (Drs. Huang, Tabrizi, and Bell), Fremont, CA.
Correspondence to: Donald A. Mahler, MD, FCCP, Section of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03756-0001; e-mail: Donald.a.mahler{at}hitchcock.org
Abstract
Study objective: To investigate the efficacy and safety of a fully human monoclonal antibody recognizing the chemokine interleukin (IL)-8 in patients with COPD.
Design: Randomized, double-blind, parallel-group, placebo-controlled trial.
Setting: Eighteen clinics/hospitals in the United States.
Patients: One hundred nine patients with stable COPD.
Interventions: Three IV infusions of either monoclonal antibody recognizing IL-8 (800-mg loading dose; 400-mg subsequent doses) or active buffer solution administered monthly over a 3-month period.
Measurements and results: The differences in the transition dyspnea index (TDI) total score, the primary outcome measure, between fully human monoclonal IgG2 antibody directed against IL-8 and placebo were 0.8, 1.0, 0.8, and 0.3 at week 2 (p = 0.046) and months 1 to 3, respectively. At all time points, the proportion of patients achieving 
1 point improvement in the TDI was greater for the monoclonal antibody group compared with the placebo group: 28% vs 11% at week 2 (p = 0.028). There were no significant differences observed for lung function, health status, 6-min walking distance, and adverse events between groups.
Conclusions: The results of this phase 2 study suggest that neutralization of IL-8 with monoclonal antibody therapy may improve dyspnea in patients with COPD. These results support the further investigation of monoclonal antibody therapy targeting IL-8 for the treatment of this disease.
Key Words: chemokine • interleukin-8 • St. George Respiratory Questionnaire • transition dyspnea index
This article has been cited by other articles:
|
|
 |
|
  B. R. Celli Update on the Management of COPD Chest, June 1, 2008; 133(6): 1451 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Siddiqui, F. Hollins, S. Saha, and C. E. Brightling Inflammatory cell microlocalisation and airway dysfunction: cause and effect? Eur. Respir. J., December 1, 2007; 30(6): 1043 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mahler, L. A. Waterman, J. Ward, C. McCusker, R. ZuWallack, and J. C. Baird Validity and Responsiveness of the Self-Administered Computerized Versions of the Baseline and Transition Dyspnea Indexes Chest, October 1, 2007; 132(4): 1283 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Mahler Mechanisms and Measurement of Dyspnea in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2006; 3(3): 234 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Inoue, H. Takano, R. Yanagisawa, T. Yoshikawa, D. A. Mahler, and G. M. Bell Interleukin-8 Neutralization for COPD Chest, July 1, 2005; 128(1): 464 - 465. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
